Background: Salbutamol, the most widely used short-acting b 2 -agonist, consists of a racemic mixture of equal amounts of two enantiomers, (R)-salbutamol and (S)-salbutamol. The bronchodilator effects of salbutamol are attributed entirely to (R)-salbutamol (levosalbutamol), while (S)-salbutamol has been shown to possess bronchospastic and pro-inflammatory effects both in vitro and in vivo studies. Levosalbutamol, the (R)-enantiomer of salbutamol is currently available only in a liquid formulation for use via a nebulizer. Recently, levosalbutamol to be administered via a pressurized metered dose inhaler (pMDI) has been developed. Aims: To compare the time-dependent bronchodilator responses of single doses of 100 mcg levosalbutamol and 200 mcg racemic salbutamol administered via a pMDI in subjects with stable mild-to-moderate bronchial asthma over a period of 6 h. Methods: Single doses of 100 mcg levosalbutamol, 200 mcg salbutamol and placebo were administered with a pMDI in 30 stable asthmatic subjects in a randomized, double-blind, placebo-controlled, three-way cross over study. Forced expiratory volume in 1 s (FEV 1 ) and forced vital capacity (FVC) were measured at baseline, and over 6 h post-study drug administration.
Introduction
Salbutamol (Albuterol) is the most widely used short-acting b 2 -agonist in the symptomatic relief of asthma and chronic obstructive pulmonary disease (COPD). In all formulations, salbutamol consists of a racemic mixture of equal amounts (50:50) of (R)-and (S)-isomers. 1 Although these isomers are chemically identical, they differ in conformation, being exact non-superimposable (mirror) images of one another, or stereoisomers. 2 (R)-salbutamol has been shown to have a 2-fold greater binding affinity than racemic salbutamol and a 100-fold greater binding affinity than (S)-salbutamol for the b 2 -adrenergic receptor. 3 As a result, the bronchodilator property of racemic (R,S)-salbutamol is attributed entirely to (R)-salbutamol. Clinical studies, especially in children have shown that levosalbutamol produces a similar bronchodilator response as racemic salbutamol even when administered at one-half or one-fourth the dose. [4] [5] [6] [7] [8] [9] (S)-salbutamol has no clinically meaningful ability to relax airway smooth muscle. Pre-clinical studies have suggested that (S)-salbutamol might antagonize the smooth muscle relaxing actions of (R)-salbutamol by increasing intracellular Ca 2+ levels. 10 (S)-salbutamol given alone has also been reported to enhance airway hyperresponsiveness to spasmogens in vitro, promote eosinophil recruitment and activation, increase the production of histamine, and increase airway smooth muscle contractility. 11 These divergent properties of (R)-and (S)-salbutamol suggest that administration of only (R)-salbutamol would have a better therapeutic index than racemic salbutamol.
Although levosalbutamol [(R)-salbutamol] has been introduced in the management of asthma and COPD since 1999, it is available only in a liquid formulation to be administered by a nebulizer. The pressurized metered dose (pMDI) inhaler is the most widely used device for drug delivery in patients with asthma. It is convenient, cheap, easy to use and effective. 12 Salbutamol administered via pMDI is widely used in the management of symptomatic relief of acute asthma, and when administered via a spacer, is as effective as that administered via a nebulizer in patients with acute severe exacerbations. 13 Recently, levosalbutamol has been developed to be delivered via a pMDI (50 mcg per puff). The aim of this study was to compare the time-dependent bronchodilator effects of single doses of 100 mcg levosalbutamol and 200 mcg racemic salbutamol, both administered by a pMDI in subjects with chronic stable mild-to-moderate asthma.
Study design
Male and female stable asthmatic subjects between the age groups of 18-65 years were recruited into the study. Asthma was defined according to American Thoracic Society (ATS) criteria (history suggestive of asthma, improvement in forced expiratory volume in 1 s (FEV 1 ) of at least 12% and 200 mL with 200 mcg racemic salbutamol).
14 All the study subjects were non-smokers and none of them received oral steroids or had an acute asthma exacerbation 4 weeks prior to the start of the study. Those subjects who were on regular (at least 4 weeks duration) inhaled corticosteroids were allowed to continue with their medication at the same dose throughout the entire duration of the study. All subjects had a baseline FEV 1 of at least 60% predicted [calculated as per European Community for Coal and Steel (ECCS) X 0.9] 15 and underwent assessment for the proper use of a pMDI. Pregnant and lactating women were exempted from the study. Peripheral venous blood was analyzed for routine hemogram and biochemistry during the screening visit to rule out other associated disorders. The study was approved by the institutional ethics committee and a written informed consent was obtained from all study subjects.
Single doses of 100 mcg levosalbutamol, 200 mcg racemic salbutamol and placebo (manufactured by Cipla Ltd. India) were administered on three separate study days, at least 3 days apart, in a randomized, double-blinded, crossover manner via a pMDI and a non-static spacer (Zerostat TM spacer, Cipla Ltd., India). The propellant used in this study was CFC (Chlorofluorocarbons) comprising of trichlorofluromethane and dichlorofluromethane. Care was taken to ensure that the subjects had avoided short-acting b 2 -agonists for at least 8 h and long-acting b 2 -agonists and oral theophyllines for at least 24 h prior to the start of the study visits. Lung function parameters (FEV 1 and forced vital capacity (FVC)) were measured before (baseline values) and 5, 15, 30, 60, 120, 240 and 360 min after the study drug administration using a volume-based bellows Gold Standard Vitalograph s Spirometer. The lung function tests were performed by a trained lung function technician using ATS guidelines. 16 The highest FEV 1 value at each time point was considered for analysis. The difference of up to 12% in the baseline FEV 1 between the two study visits was accepted. Blood was collected for the measurement of serum potassium levels before and 1 h after the administration of the study medications. Pulse rate was measured before, 1 and 6 h after the administration of study drug medications.
The primary efficacy parameter was the mean difference in area under the curve (AUC) for percent change in FEV 1 and FVC from baseline to 6 h. The secondary efficacy parameters were the mean maximum FEV 1 and FVC change from baseline, time to onset of response, time to maximum response and duration of response. The time to onset of bronchodilator response was defined as an increase in FEV 1 of 12% and 200 mL from the baseline value, while the duration of action was taken as the previous time point when the fall in FEV 1 was at least 200 mL from the baseline value. The safety parameters assessed were mean changes in pulse rate and serum potassium levels from baseline values to 1 h after study medications.
Sample size estimation for this study was done using a PS (Power and Sample Size) Software Version 2.1.31 (Vanderbilt, Canada) considering the mean maximum change in FEV 1 following salbutamol administration from our previous study. A sample size of 24 was required to detect differences between study medications with 80% power to show equivalence at a significance level of 5%.
Spirometric data (FEV 1 , FVC) for each study treatment were analyzed using student's t-test for paired variables. The mean response to all treatments was compared by multi-factorial analyses of variance (ANOVA) to determine the overall effect of interventions. Duncan's multiple range testing with 95% confidence interval (CI) was used where the differences were significant (Po0.05). The AUC for FEV 1 was calculated for each subject during each study treatment using the trapezoidal rule. The mean difference in the AUC for the two treatment groups were analyzed using ANOVA approach for Schuirmann's two one-sided test of equivalence. Equivalence was accepted if the mean difference with 95% CI's of the study variables were contained within the set limits. An independent statistician who was blinded to the codes for the study medications performed the statistical analysis. The medication codes were broken at the end of the complete analysis.
Results
Forty-two subjects were screened for the study and 30 were randomized (11 subjects did not meet the criteria for either airflow reversibility or percent FEV 1 predicted, while one subject withdrew consent). All the subjects completed the study without any significant adverse effects. The mean age of the study population was 44.8 (711.0) years. The summary of the demographic details is shown in Table 1 .
There was no significant difference in the baseline FEV 1 values on the 2 study days (mean7SD for levosalbutamol was 1.7570.63 and racemic salbutamol was 1.7770.66; P ¼ 0:28).
Single doses of 100 mcg levosalbutamol and 200 mcg racemic salbutamol produced a significantly better timedependent bronchodilator response as measured by AUC percentage change for FEV 1 and FVC from baseline to 6 h when compared to placebo (P values o0.0001 for FEV 1 and o0.0001 for FVC) (Fig. 1) . The mean differences in AUC for percent change in FEV 1 and FVC between racemic salbutamol and levosalbutamol from baseline to 6 h were not significant [(FEV 1 AUC 0À6 h : 7486.3 versus 7493.6 for levosalbutamol and salbutamol respectively; P40:05) (FVC AUC 0À6 h : 3814.8 versus 3463.2 for levosalbutamol and salbutamol, respectively; P40:05)] (Fig. 1 showing FEV 1 % change), suggesting that 100 mcg levosalbutamol and 200 mcg racemic salbutamol produced equivalent bronchodilator responses over 6 h.
The mean maximum difference for FEV 1 from baseline was 537 mL with levosalbutamol and 538 mL with racemic salbutamol, while the mean maximum difference for FVC was 456 and 417 mL, respectively (Fig. 2) . These differences were not statistically significant, suggesting that 100 mcg levosalbutamol and 200 mcg racemic salbutamol produced an equivalent mean maximum increase in FEV 1 and FVC.
Levosalbutamol took 58.3 and 52.6 min to reach the maximum FEV 1 and FVC response, while racemic salbutamol took 67.5 and 64.3 min, respectively. These differences were not statistically significant when compared to each other (P ¼ 0:94). The time to onset for the bronchodilator response (increase of at least 200 mL and 12% in FEV 1 from baseline) for levosalbutamol was 12 min, while that for racemic salbutamol was 18 min and the differences between the two were not significant. The mean duration of response (difference between onset and termination of effect) for levosalbutamol was 208 min and for racemic salbutamol was 212 min. This difference was not statistically significant (P ¼ 0:75), suggesting that there was no difference in the duration of bronchodilator response between the two study drugs.
ARTICLE IN PRESS
Both levosalbutamol and racemic salbutamol produced a significant decrease in serum potassium level 1 h after study drug administration compared to their respective baseline values, (4.61-4.25; Po0.001 and 4.39-4.13; P ¼ 0:004, respectively). The placebo treatment did not show any significant decline in serum potassium levels (4.47-4.37; P ¼ 0:19). Racemic salbutamol and levosalbutamol 60 min post-drug administration both produced a significant increase in pulse rate versus their baseline, (73.9-77.8 beats/ min; Po0.05 and 72.4-77.3 beats/min; Po0.05, respectively). There was no significant difference in the pulse rate 6 h post-drug administration compared to baseline values (data not shown).
Discussion
In this randomized, double-blind, placebo-controlled, crossover study, we have demonstrated for the first time that a single dose of 100 mcg of levosalbutamol administered via a pMDI produced a similar time-dependent bronchodilator response as that of 200 mcg racemic salbutamol in subjects with mild-to-moderate stable asthma. The time to onset of bronchodilator response, mean maximum change in FEV 1 and FVC, time to reach the mean maximum FEV 1 and FVC responses and the duration of responses were similar between the two study medications. Both the drugs increased pulse rate and reduced serum potassium levels equally, when measured 1 h after administration.
Salbutamol is the most widely used inhaled short-acting b 2 -agonist in the symptomatic relief of asthma and COPD. It consists of a racemic mixture of equal amounts of (R)-and (S)-enantiomers. These enantiomers have similar physical and chemical properties, but have different receptor specificity and therefore have different pharmacological and physiological effects. The bronchodilator properties of racemic salbutamol (R,S) have been shown to be attributed entirely to the (R)-enantiomer. Human epinephrine produced by the adrenal gland occurs only in the (R)-isomer form. Clinical studies have demonstrated that the bronchodilator and bronchoprotective effects of racemic salbutamol in subjects with asthma lie entirely with the (R)-isomer, with the (S)-isomer being inert. Moreover, in vitro cellular data have implicated (S)-salbutamol as a possible cause of airway hyperreactivity, bronchoconstriction or inflammation, 17, 18 perhaps induced by stimulating intracellular calcium accumulation and inhibiting adenyl cyclase. 6, 19, 20 These pre-clinical findings have been confirmed in some clinical studies that show a greater bronchodilation with levosalbutamol compared to salbutamol when given either as a long-term therapy 6 (4 weeks) or when given in a single dose. 19 This leads to an increase in the therapeutic index of levosalbutamol when compared to racemic salbutamol. These divergent pharmacologic properties form the scientific rationale for the potential advantages of levosalbutamol over racemic salbutamol in the treatment of asthma and other airway disorders.
Until recently, optically pure isomers of b 2 -agonists were not available or were not thought necessary for optimum clinical safety or efficacy in acute asthma treatment. The availability of purified (R)-salbutamol (levosalbutamol) and the United States Food and Drug Administration's position to quantify the safety of racemic drugs have generated renewed interest in the role of inert isomers. In this study, we compared the bronchodilator effects of single doses of 100 mcg levosalbutamol and 200 mcg racemic salbutamol administered via a pMDI in subjects with asthma over a period of 6 h. These dosages were used to simulate those used in routine clinical practice. To our knowledge, this is the first reported study that has investigated the efficacy and safety of a single dose of levosalbutamol administered via a pMDI.
Our study demonstrates that 100 mcg levosalbutamol administered in a pMDI formulation is as effective as 200 mcg racemic salbutamol, when measured by percentage changes in FEV 1 and FVC AUCs from baseline to 6 h, time to onset of bronchodilator response, mean maximum change in FEV 1 and FVC and duration of the bronchodilator effect. The results of this study confirm earlier reports that the bronchodilator effects of salbutamol are entirely attributable to its (R)-enantiomer.
Although earlier studies 19, 20 had suggested that levosalbutamol might show lesser clinical side effects than the racemic form, we did not find any difference in pulse rates and decreases in serum potassium levels between levosalbutamol and racemic salbutamol. These observations are in accordance with Lotvall et al. 5 who have demonstrated that the adverse effects of racemic salbutamol on heart rate and potassium levels are mediated mainly by the (R)-enantiomer. Cockcroft et al. have reported that nebulized levosalbutamol produced similar effects on heart rate as racemic salbutamol, suggesting that tachycardia caused by salbutamol is attributed to (R)-salbutamol. Pancu et al. 21 have reported that (R)-salbutamol and racemic salbutamol are equally effective in lowering serum potassium levels. This study has therefore shown that the bronchodilator effect and systemic side effects of salbutamol reside with the (R)-enantiomer. We did not assess tremors. Since we used single doses of 100 mcg levosalbutamol and 200 mcg of racemic salbutamol we did not expect to find significant numbers of patients experiencing tremors at this small dose. Also tremor assessment is a subjective observation, which has its own drawbacks. In summary, a single dose of levosalbutamol administered in a pMDI formulation produced an equivalent timedependent bronchodilator response over 6 h as racemic salbutamol at half the dose. Thus, levosalbutamol administered in a pMDI formulation may be used routinely for acute symptomatic relief in subjects with asthma. Further studies involving larger numbers of patients and for longer duration are required to determine long-term safety and efficacy of levosalbutamol administered via a pMDI.
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